SB 666 · 2026 · Senate · Health and Human Services Committee
Health care transaction oversight
AI-generatedrelative to consumer protection, transparency, and oversight of certain health care transactions and establishing a study committee to analyze health insurance providers, their practices, policies, premiums, management, and the impact to consumers.
Regulates material health care transactions by requiring notice to the department of justice, authorizes departmental review and enforcement under the consumer protection act, and establishes a legislative committee to study health insurance providers and their impact on consumers.AI-generated
Status
Referred to interim study (Senate) · March 6, 2026- ✓Introduced
- ✕Senate
- House
- Governor
- Law
Analysis
This bill: I. Defines and regulates material health care transactions, and requires notice to the department of justice of health care transactions that change of control of a health care entity and that may reasonably be expected to affect competition, cost of health care services, or access to care. The bill authorizes the department to review, monitor, and approve such transactions and enforce violations of the regulatory requirements as a violation of the consumer protection act. II. Establishes a legislative committee to study health insurance providers, their practices, policies, premiums, management, and the impact to consumers.
From the bill's official ANALYSIS section.
In the bill's words
Quoted verbatim from the bill as introduced. Passages chosen from the operative text.Computed by this site
“"Affected health care entity" means any hospital, health system, clinic, ambulatory surgical center, urgent care center, diagnostic facility, physician practice, or other entity licensed or certified to provide health care services in this state.”
“Parties engaging in a material health care transaction shall file written notice with the department at least 60 days prior to the proposed closing date.”
“The department shall review a material health care transaction within 30 days of receipt of notice under RSA 358-U:2 to determine its likely impact on:”
“No private equity entity, for-profit owner, or management services organization shall interfere with, direct, or control the professional clinical judgment of a licensed health care professional in the diagnosis, treatment, or care of a patient.”
Official record
gc.nh.gov · the authoritative source
Sponsors
- Sen. Rebecca Perkins KwokaDMinority Leader
- Sen. Cindy RosenwaldDDeputy Democratic Leader
- Sen. Suzanne PrentissDAssistant Democratic Leader
Also: Sen. Donovan FentonD, Sen. Tara ReardonD, Sen. Pat LongD, Sen. David WattersD
Public testimony
No one submitted online testimony on this bill. See the record
Votes
yeanay- Mar 12, 2026SenateCommittee report: Referred to Interim Study5–0Overall100% yea
- Mar 12, 2026SenateVoice voteRefer to Interim Studyadopted
Hearings and debates
- Feb 18, 2026Public hearingSenate Health and Human Services5:01–9:574m 56slocated in the stream transcriptHearing
- Mar 12, 2026Floor debateSenate floorWatchnot located in the transcript — opens the full streamCommittee Report: Referred to Interim Study; Refer to Interim Study — adopted, voice vote
Timestamps locate where this bill is taken up in the chamber's YouTube stream.
Legislative history
- Jan 29, 2026SenIntroduced 01/29/2026 and Referred to Health and Human Services; SJ 3
- Feb 18, 2026SenHearing: 02/18/2026, Room 100, SH, 09:00 am; SC 6
- Mar 12, 2026Sen: Referred to Interim Study, 03/12/2026; Vote 5-0; CC; SC 9
- Mar 12, 2026SenRefer to Interim Study, MA, VV; 03/12/2026; SJ 6
Coverage
No reporting linked yet.
Documents (PDF)
Bill text & amendments link direct to gc.nh.gov; committee reports stream from the state record.